Tiziana Life Sciences Ltd Ordinary Shares TLSA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TLSA is a good fit for your portfolio.
News
-
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
-
Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program
-
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
-
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
-
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
-
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
-
Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease
-
Nvidia climbs, D.R. Horton gets a Buffett boost, and other stocks on the move
Trading Information
- Previous Close Price
- $0.79
- Day Range
- $0.75–0.88
- 52-Week Range
- $0.41–1.27
- Bid/Ask
- $0.80 / $0.83
- Market Cap
- $84.37 Mil
- Volume/Avg
- 889,692 / 166,780
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of highly qualified executives with extensive drug development and commercialization experience.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 9
Comparables
Valuation
|
Metric
|
TLSA
|
KNSA
|
03681
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 97.83 | — |
Price/Book Value | 12.17 | 2.92 | 6.03 |
Price/Sales | — | 4.27 | 1,280.34 |
Price/Cash Flow | — | 107.48 | — |
Price/Earnings
TLSA
KNSA
03681
Financial Strength
|
Metric
|
TLSA
|
KNSA
|
03681
|
|---|---|---|---|
Quick Ratio | 3.85 | 3.58 | 1.89 |
Current Ratio | 3.85 | 4.34 | 1.96 |
Interest Coverage | −1,624.08 | — | −46.15 |
Quick Ratio
TLSA
KNSA
03681
Profitability
|
Metric
|
TLSA
|
KNSA
|
03681
|
|---|---|---|---|
Return on Assets (Normalized) | −55.79% | 8.64% | −29.01% |
Return on Equity (Normalized) | −116.34% | 10.14% | −57.52% |
Return on Invested Capital (Normalized) | −69.44% | 9.90% | −32.84% |
Return on Assets
TLSA
KNSA
03681
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mtxvspsw | Kjg | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xbfmchqk | Hbmqt | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ctghtpzmg | Vdczth | $99.5 Bil | |
MRNA
| Moderna Inc | Xkslmyrxl | Wmjw | $38.8 Bil | |
ARGX
| argenx SE ADR | Rpdjxnms | Sqynn | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Sgvljpzv | Qgbdt | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xndmhkht | Tsnjqf | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hytwhhcck | Xbtpclv | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Prgqnqml | Wwcfh | $12.5 Bil | |
INCY
| Incyte Corp | Hnxhvcr | Wcrckf | $11.6 Bil |